Literature DB >> 6323994

Transformation of NIH 3T3 cells by a human c-sis cDNA clone.

M F Clarke, E Westin, D Schmidt, S F Josephs, L Ratner, F Wong-Staal, R C Gallo, M S Reitz.   

Abstract

The mechanism of leukaemogenic transformation by human T-cell leukaemia/lymphoma virus (HTLV), a retrovirus implicated in the aetiology of certain adult T-cell leukaemias and lymphomas, is unknown but is conceivably associated with the expression of the cellular analogues of retroviral oncogenes. The HUT-102 cell line, derived from a cutaneous T-cell lymphoma and infected with HTLV, expresses several cellular oncogenes. It is unusual among haemopoietic cell lines in that one of these is c-sis, the gene from which the oncogene v-sis of the simian sarcoma virus was derived, and perhaps the gene for platelet-derived growth factor (PDGF). To explore the possible role of c-sis expression in HTLV-induced disease, we have obtained cDNA clones of c-sis from HUT-102 cells. Here we describe two such clones and report that one of them transforms NIH-3T3 cells. This is the first example of transformation of NIH-3T3 cells by a human onc gene other than c-ras or Blym, as well as the first demonstration of transformation by a human cDNA clone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323994     DOI: 10.1038/308464a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

1.  The human interleukin-2 receptor beta-chain gene: genomic organization, promoter analysis and chromosomal assignment.

Authors:  H Shibuya; M Yoneyama; Y Nakamura; H Harada; M Hatakeyama; S Minamoto; T Kono; T Doi; R White; T Taniguchi
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

Review 2.  Platelet-derived growth factor: mechanism of action and possible in vivo function.

Authors:  C H Heldin; B Westermark
Journal:  Cell Regul       Date:  1990-07

3.  Isolation of recessive (mediator-) revertants from NIH 3T3 cells transformed with a c-H-ras oncogene.

Authors:  H Yamada; T Omata-Yamada; N Wakabayashi-Ito; S G Carter; P Lengyel
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

4.  Platelet-derived growth factor agonist activity of a secreted form of the v-sis oncogene product.

Authors:  A Johnsson; C Betsholtz; K von der Helm; C H Heldin; B Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

5.  Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity.

Authors:  E B Leof; J A Proper; A S Goustin; G D Shipley; P E DiCorleto; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  Isolation and sequencing of a cDNA clone homologous to the v-sis oncogene from human endothelial cells.

Authors:  B D Tong; S E Levine; M Jaye; G Ricca; W Drohan; T Maciag; T F Deuel
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

7.  Regulation of expression of the c-sis proto-oncogene.

Authors:  L Ratner
Journal:  Nucleic Acids Res       Date:  1989-06-12       Impact factor: 16.971

8.  Suramin inhibits binding and degradation of platelet-derived growth factor in arterial smooth muscle cells but does not interfere with autocrine stimulation of DNA synthesis.

Authors:  M Sjölund; J Thyberg
Journal:  Cell Tissue Res       Date:  1989-04       Impact factor: 5.249

9.  Sequences of the 5' portion of the human c-sis gene: characterization of the transcriptional promoter and regulation of expression of the protein product by 5' untranslated mRNA sequences.

Authors:  L Ratner; B Thielan; T Collins
Journal:  Nucleic Acids Res       Date:  1987-08-11       Impact factor: 16.971

10.  Molecular and physical arrangements of human DNA in HRAS1-selected, chromosome-mediated transfectants.

Authors:  D J Porteous; J E Morten; G Cranston; J M Fletcher; A Mitchell; V van Heyningen; J A Fantes; P A Boyd; N D Hastie
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.